FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023695436> ?p ?o ?g. }

• W2023695436 endingPage "187" @default.
• W2023695436 startingPage "179" @default.
• W2023695436 abstract "To investigate the efficacy and tolerability of albiglutide, a weekly glucagon-like peptide-1 receptor agonist, when added to metformin and glimepiride in a triple therapy regimen in people with type 2 diabetes mellitus.This was a 156-week, randomized, double-blind, parallel-group, multicentre study. In the present paper we describe the primary results, namely those at 52 weeks. Adult participants (n = 685) were randomly assigned to albiglutide (30 mg/week), pioglitazone (30 mg/day) or placebo. If needed, blinded uptitration of albiglutide (to 50 mg/week) and pioglitazone (to 45 mg/day) was allowed. The participant's current dose of metformin (>1500 mg/day) was maintained throughout. The glimepiride dose (4 mg/day), standardized before randomization, could be decreased if persistent hypoglycaemia occurred.The week 52 model-adjusted difference in change of glycated haemoglobin (primary endpoint) for albiglutide versus placebo was -0.87 [95% confidence interval (CI) -1.07, -0.68]%-units (p < 0.001), and for albiglutide versus pioglitazone it was 0.25 (95% CI 0.10, 0.40)%-units; therefore, not non-inferior. In the albiglutide group only, fasting plasma glucose reduced rapidly in the first 2 weeks. Confirmed hypoglycaemia occurred in 14% of participants on albiglutide, 25% on pioglitazone and 14% on placebo. The mean (± standard error) weight change was -0.42 (±0.2) kg with albiglutide, +4.4 (±0.2) kg (p < 0.001) with pioglitazone, and -0.40 (±0.4) kg with placebo and serious adverse events occurred in 6.3, 9.0 and 6.1% of participants in the respective groups. Injection site reactions occurred in 13% of participants on albiglutide and resulted in treatment discontinuation for four participants (1.4%).Albiglutide, as part of triple therapy, provided effective glucose-lowering and was generally well tolerated." @default.
• W2023695436 created "2016-06-24" @default.
• W2023695436 creator A5004846236 @default.
• W2023695436 creator A5005407036 @default.
• W2023695436 creator A5015234811 @default.
• W2023695436 creator A5026021005 @default.
• W2023695436 creator A5058856546 @default.
• W2023695436 creator A5062849136 @default.
• W2023695436 creator A5087844534 @default.
• W2023695436 date "2014-12-10" @default.
• W2023695436 modified "2023-10-02" @default.
• W2023695436 title "Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5" @default.
• W2023695436 cites W1969151129 @default.
• W2023695436 cites W1975588287 @default.
• W2023695436 cites W1988527243 @default.
• W2023695436 cites W2043900831 @default.
• W2023695436 cites W2050984323 @default.
• W2023695436 cites W2057913111 @default.
• W2023695436 cites W2062628516 @default.
• W2023695436 cites W2071835038 @default.
• W2023695436 cites W2081276121 @default.
• W2023695436 cites W2091977092 @default.
• W2023695436 cites W2097395605 @default.
• W2023695436 cites W2101244337 @default.
• W2023695436 cites W2107949845 @default.
• W2023695436 cites W2114542756 @default.
• W2023695436 cites W2128825255 @default.
• W2023695436 cites W2138077952 @default.
• W2023695436 cites W2152569314 @default.
• W2023695436 cites W2152984355 @default.
• W2023695436 cites W2161551526 @default.
• W2023695436 cites W2162934281 @default.
• W2023695436 cites W2164535707 @default.
• W2023695436 cites W2172193326 @default.
• W2023695436 cites W2596624061 @default.
• W2023695436 cites W4242364069 @default.
• W2023695436 doi "https://doi.org/10.1111/dom.12414" @default.
• W2023695436 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25406730" @default.
• W2023695436 hasPublicationYear "2014" @default.
• W2023695436 type Work @default.
• W2023695436 sameAs 2023695436 @default.
• W2023695436 citedByCount "79" @default.
• W2023695436 countsByYear W20236954362014 @default.
• W2023695436 countsByYear W20236954362015 @default.
• W2023695436 countsByYear W20236954362016 @default.
• W2023695436 countsByYear W20236954362017 @default.
• W2023695436 countsByYear W20236954362018 @default.
• W2023695436 countsByYear W20236954362019 @default.
• W2023695436 countsByYear W20236954362020 @default.
• W2023695436 countsByYear W20236954362021 @default.
• W2023695436 countsByYear W20236954362022 @default.
• W2023695436 countsByYear W20236954362023 @default.
• W2023695436 crossrefType "journal-article" @default.
• W2023695436 hasAuthorship W2023695436A5004846236 @default.
• W2023695436 hasAuthorship W2023695436A5005407036 @default.
• W2023695436 hasAuthorship W2023695436A5015234811 @default.
• W2023695436 hasAuthorship W2023695436A5026021005 @default.
• W2023695436 hasAuthorship W2023695436A5058856546 @default.
• W2023695436 hasAuthorship W2023695436A5062849136 @default.
• W2023695436 hasAuthorship W2023695436A5087844534 @default.
• W2023695436 hasConcept C126322002 @default.
• W2023695436 hasConcept C126894567 @default.
• W2023695436 hasConcept C134018914 @default.
• W2023695436 hasConcept C142724271 @default.
• W2023695436 hasConcept C197934379 @default.
• W2023695436 hasConcept C204787440 @default.
• W2023695436 hasConcept C27081682 @default.
• W2023695436 hasConcept C2776307423 @default.
• W2023695436 hasConcept C2777180221 @default.
• W2023695436 hasConcept C2778375690 @default.
• W2023695436 hasConcept C2778384471 @default.
• W2023695436 hasConcept C2779306644 @default.
• W2023695436 hasConcept C2780323712 @default.
• W2023695436 hasConcept C2781413609 @default.
• W2023695436 hasConcept C555293320 @default.
• W2023695436 hasConcept C71924100 @default.
• W2023695436 hasConceptScore W2023695436C126322002 @default.
• W2023695436 hasConceptScore W2023695436C126894567 @default.
• W2023695436 hasConceptScore W2023695436C134018914 @default.
• W2023695436 hasConceptScore W2023695436C142724271 @default.
• W2023695436 hasConceptScore W2023695436C197934379 @default.
• W2023695436 hasConceptScore W2023695436C204787440 @default.
• W2023695436 hasConceptScore W2023695436C27081682 @default.
• W2023695436 hasConceptScore W2023695436C2776307423 @default.
• W2023695436 hasConceptScore W2023695436C2777180221 @default.
• W2023695436 hasConceptScore W2023695436C2778375690 @default.
• W2023695436 hasConceptScore W2023695436C2778384471 @default.
• W2023695436 hasConceptScore W2023695436C2779306644 @default.
• W2023695436 hasConceptScore W2023695436C2780323712 @default.
• W2023695436 hasConceptScore W2023695436C2781413609 @default.
• W2023695436 hasConceptScore W2023695436C555293320 @default.
• W2023695436 hasConceptScore W2023695436C71924100 @default.
• W2023695436 hasFunder F4320307773 @default.
• W2023695436 hasIssue "2" @default.
• W2023695436 hasLocation W20236954361 @default.
• W2023695436 hasLocation W20236954362 @default.
• W2023695436 hasOpenAccess W2023695436 @default.
• W2023695436 hasPrimaryLocation W20236954361 @default.

• next